CD20 Antibody - #DF13319

(3)   (8)  
Product: CD20 Antibody
Catalog: DF13319
Description: Rabbit polyclonal antibody to CD20
Application: WB IHC IF/ICC
Reactivity: Human
Prediction: Pig, Bovine, Sheep, Dog
Mol.Wt.: 33kDa; 33kD(Calculated).
Uniprot: P11836
RRID: AB_2846338

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
IF/ICC 1:100-1:500, WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Prediction:
Pig(88%), Bovine(88%), Sheep(88%), Dog(88%)
Clonality:
Polyclonal
Specificity:
CD20 Antibody detects endogenous levels of total CD20.
RRID:
AB_2846338
Cite Format: Affinity Biosciences Cat# DF13319, RRID:AB_2846338.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

APY; ATOPY; B lymphocyte antigen CD20; B Lymphocyte Cell Surface Antigen B1; B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; B-lymphocyte surface antigen B1; B1; Bp 35; Bp35; CD 20; CD20; CD20 antigen; CD20 receptor; CD20_HUMAN; CVID5; Fc epsilon receptor I beta chain; Fc Fragment of IgE high affinity I receptor for beta polypeptide; FCER1B; High affinity immunoglobulin epsilon receptor subunit beta; IgE Fc receptor subunit beta; IGEL; IGER; IGHER; LEU 16; LEU16; leukocyte surface antigen Leu 16; Leukocyte surface antigen Leu-16; Ly44; Membrane spanning 4 domains A1; Membrane spanning 4 domains subfamily A member 2; Membrane-spanning 4-domains subfamily A member 1; MGC3969; MS4A1; MS4A2; S7;

Immunogens

Immunogen:
Uniprot:

P11836(CD20_HUMAN) >>Visit HPA database.

Gene(ID):
MS4A1(931)
Expression:
P11836 CD20_HUMAN:

Expressed on B-cells.

Sequence:
MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
88
Bovine
88
Sheep
88
Dog
88
Rabbit
75
Horse
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P11836 As Substrate

Site PTM Type Enzyme
T2 Phosphorylation
T3 Phosphorylation
S7 Phosphorylation
T11 Phosphorylation
S25 Phosphorylation
S35 Phosphorylation
S36 Phosphorylation
T41 Phosphorylation
S121 Phosphorylation
S225 Phosphorylation
S231 Phosphorylation P68400 (CSNK2A1) , P19784 (CSNK2A2)
K235 Ubiquitination
K236 Ubiquitination
K243 Ubiquitination
T250 Phosphorylation P68400 (CSNK2A1) , P19784 (CSNK2A2)
S253 Phosphorylation
S254 Phosphorylation
S289 Phosphorylation P68400 (CSNK2A1) , P19784 (CSNK2A2)

Research Backgrounds

Function:

B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR.

PTMs:

Phosphorylated on serines and threonines in resting B-cells. Protein kinase C/PKC can use CD20 as substrate.

Subcellular Location:

Cell membrane>Multi-pass membrane protein. Cell membrane>Lipid-anchor.
Note: Constitutively associated with membrane rafts.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed on B-cells.

Subunit Structure:

Forms homotetramers. Interacts with the heavy and light chains of cell surface IgM, the antigen-binding components of the BCR.

Family&Domains:

Belongs to the MS4A family.

Research Fields

· Organismal Systems > Immune system > Hematopoietic cell lineage.   (View pathway)

References

1). Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation. Frontiers in Immunology (PubMed: 37638036) [IF=7.3]

Application: IHC    Species: Human    Sample:

Figure 3 Representative images and data reporting hematoxylin and eosin staining, CD3, CD20, GATA3 and T-bet staining of APRC, AD and HC samples. Magnification: ×40, ×200, AD, atopic dermatitis, ARPC, acquired reactive perforating collagenosis, HC, healthy control, HE, hematoxylin and eosin.
2). Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20. CANCER SCIENCE (PubMed: 34252986) [IF=5.7]

Application: IF/ICC    Species: Human    Sample: DLBCL cells

FIGURE 4 Pyruvate dehydrogenase kinase 4 (PDK4) has a negative regulatory effect on MS4A1/CD20 expression in diffuse large B- cell lymphoma cells. A, B, Real- time quantitative PCR analysis of PDK4 and MS4A1 mRNA expression in U2932 and OCI- Ly8 cells transfected with PDK4 overexpressing (PDK4 OE) plasmid or empty vector (EV). C, D, CD20 (green) molecules in the plasma membrane showed a reduction after PDK4 overexpression in both U2932 and OCI- Ly8 cells. Scale bar, 15 μm. E, F, Western blot analysis of PDK4 and CD20 protein levels in U2932 and OCI- Ly8 cells with PDK4 shRNA interference or transfected with PDK4 OE plasmid or EV. *P < .05, **P < .01, ***P < .001

Application: WB    Species: Human    Sample: DLBCL cells

FIGURE 2 High pyruvate dehydrogenase kinase 4 (PDK4) is associated with rituximab (RTX) resistance and low MS4A1/CD20 in diffuse large B- cell lymphoma (DLBCL) cells. A, B, Real- time quantitative PCR analysis of PDK4 and MS4A1 mRNA expression in DLBCL cell lines U2932, OCI- ly7, and OCI- ly8. C, Western blot analysis of PDK4 and CD20 protein levels in DLBCL cell lines U2932, OCI- ly7, and OCI- ly8. D, E, Annexin V- phycoerythrin (PE)/7- AAD double staining analysis of the three DLBCL cell lines treated with RTX (50 μg/mL). F, G, Mitochondrial membrane potential of DLBCL cells following treatment with RTX for 48 hours and stained with JC- 1 probe. Representative pictures of JC- 1 staining are shown. Scale bar, 25 μm. ***P < .001
3). PDK4-Mediated Metabolic Reprogramming Promotes Rituximab Resistance in Diffuse Large B-Cell Lymphoma Via Negative Regulation of MS4A1/CD20. Research Square

Application: WB    Species: Human    Sample: DLBCL cells

Figure 2. High PDK4 is associated with rituximab (RTX) resistance and low MS4A1/CD20 in DLBCL cells. A and B, qRT-PCR analysis of PDK4 and MS4A1 mRNA expression in DLBCL cell lines U2932, OCI-ly7 and OCI-ly8. C, western blotting analysis of PDK4 and CD20 protein levels in DLBCL cell lines U2932, OCI-ly7 and OCI-ly8. D and E, annexin V-FITC/PI double staining analysis of the three DLBCL cell lines treated with rituximab (50 μg/ml).

Application: IF/ICC    Species: Human    Sample: DLBCL cells

Figure 2. High PDK4 is associated with rituximab (RTX) resistance and low MS4A1/CD20 in DLBCL cells. A and B, qRT-PCR analysis of PDK4 and MS4A1 mRNA expression in DLBCL cell lines U2932, OCI-ly7 and OCI-ly8. C, western blotting analysis of PDK4 and CD20 protein levels in DLBCL cell lines U2932, OCI-ly7 and OCI-ly8. D and E, annexin V-FITC/PI double staining analysis of the three DLBCL cell lines treated with rituximab (50 μg/ml).

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.